Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LNC Technology
    • LNC Platform
    • MAT2203
    • Posters & Publications
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 14, 2019 5:02pm EDT

Matinas BioPharma Announces Proposed Public Offering of Common Stock

Feb 25, 2019 8:05am EST

Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer

Jan 10, 2019 8:00am EST

Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform

Jan 03, 2019 8:20am EST

Matinas BioPharma Appoints Keith A. Kucinski, CPA, MBA as Chief Financial Officer

Dec 20, 2018 8:35am EST

Matinas BioPharma to Present at Biotech Showcase 2019

Dec 19, 2018 8:35am EST

Matinas BioPharma Appoints Harold E. Bays, M.D. to its Cardiovascular Health Scientific Advisory Board

Dec 06, 2018 9:00am EST

Matinas BioPharma Assembles World Class Scientific Advisory Board to Guide Clinical Development Strategy of Potential Best-in-Class Prescription-Only Omega-3, MAT9001

Nov 12, 2018 7:00am EST

Matinas BioPharma Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Oct 18, 2018 8:00am EDT

Matinas BioPharma Announces Issuance of Key U.S. Patent for Prescription-Only Next Generation Omega-3 MAT9001 Providing Protection Through 2033

Oct 16, 2018 8:00am EDT

Matinas BioPharma to Present at the 8th Annual Partnership Opportunities in Drug Delivery Conference

RSS
  • Prev
    • 1...
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • 20
    • ...28
    Next
    Matinas BioPharma Holdings, Inc.

    Science

    • LNC PLATFORM
    • MAT2203
    • Posters & Publications

    Investors

    • COMPANY PROFILE
    • STOCK DATA
    • ANALYST COVERAGE
    • GOVERNANCE
    • PRESS RELEASES
    • EVENTS
    • PRESENTATIONS
    • SEC FILINGS

    Company

    • OVERVIEW
    • OUR TEAM
    • NEWS
    • CAREERS
    • CONTACT US

    Register for updates

    Follow Us

    LinkedIn facebook twitter
    © 2025 Matinas BioPharma Holdings, Inc. All Rights Reserved.